| Bioactivity | VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR[1][2]. |
| Sequence | cyclo[{d-Cys}-Met-{Thz}-Arg-Leu-Arg-Gly-{Pen}] |
| Shortening | cyclo[{d-Cys}-M-{Thz}-RLRG-{Pen}] |
| Formula | C41H73N15O9S4 |
| Molar Mass | 1048.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xue Yang, et al. Preparation and In Vitro Validation of a Cucurbit[7]uril-Peptide Conjugate Targeting the LDL Receptor. J Med Chem. 2023 Jul 13;66(13):8844-8857. [2]. Angélina Acier, et al. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Commun Biol. 2021 Aug 19;4(1):987. |